A Study Looking at the Safety and Effectiveness of a COVID-19 Vaccine Plus Adjuvant in South African Adults : A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV. COVID-19

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

WHO International Clinical Trials Registry Platform - (2023) vom: 29. Mai Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: COVID-19;COVID-19
Phase: Phase 2
Recruitment Status: Completed
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 25-08-2020, Last updated: 2023-06-05

ICTRP ID:

PACTR202009726132275

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO004625366